Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Part of paid clinical trials in Goodyear, Arizona.

Sponsor
Western Regional Medical Center
Study ID
NCT02423954
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Determine Phase 2 dose of study drug

Key Dates

Start date
Apr 30, 2015
Status verified
Jun 2018
Primary completion
Nov 1, 2017
Completion
Nov 1, 2017

Study Design

Enrollment
33 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Temsirolimus 25 mg every 14 days + nivolumab
  • Experimental: Arm 2
    Irinotecan 150 mg/m2 every 14 days + nivolumab
  • Experimental: Arm 3
    Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period

Primary Outcome Measure

The recommended phase 2 dose (RP2D) of chemotherapy in combination with nivolumab in subjects with advanced cancer. [ Time Frame: up to 4 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Cancer Treatment Center of America @ Western Regional Medical CenterGoodyearArizona85338-

Find similar trials in Goodyear, AZ

By condition
Colorectal cancerLung cancerPancreatic cancer
By specialty
OncologyGI oncologyLung oncologyLung disease
By research site
Cancer Treatment Center of America @ Western Regional Medical Center· Goodyear, AZ

Related Studies